Given the crucial roles of Aβ and tau in the pathogenesis of AD, over 200 anti-AD drugs targeting these proteins have been tested in clinical trials to slow down disease progression, although only a few have received FDA approval [2]. The gene discussed is MAPT; the disease is Alzheimer disease.